Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Immugene doses first patient with Virus- CAR-T

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Oct 27, 2023 8:52am

150 Views

Post# 35703708

RE:Immugene doses first patient with Virus- CAR-T

Imugene. Yes they're competition, but competition that is ph1 clinical trials, whereas ONCY is ph3 with perhaps AA. So, we are yrs ahead & have the better therapy...now....but with Coffey at the helm for BD, will Pela ever get to a major who can get it to market? Oncy was caught up to and surpassed in mBC, it seems. Will Coffey finally NOT let investors down? Stay tuned...cue the sycophantic cheer crew (all one guy...hi Azz!!)

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland